AllergyTalk Episode 46 - Can We Achieve Clinical Remission in Asthma?
Price: FREE for members and non-members
Speakers: Gerald Lee, MD, FACAAI; Stanley Fineman, MD, FACAAI; and Timothy Chow, MD
Listeners can earn credit by completing the posttest questions
AllergyTalk is a podcast designed to provide easy access to research summaries from Allergy Watch and recommendations from subject matter experts in order to bring physicians up to date onthe latest advances in the field of allergy and immunology.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this podcast, the participant should be able to:
1. Discuss the characteristics of patients who achieved remission of asthma in the UK Severe Asthma Registry with biologic therapy.
2. Discuss the effect of prehospital corticosteroid administration on outcomes of anaphylaxis treated in the emergency department.
All relevant financial relationships with ineligible companies have been mitigated.
Gerald Lee, MD
Speaker: Novartis
Stanley Fineman, MD
No relevant financial relationships with ineligible companies to disclose
Timothy Chow, MD
No relevant financial relationships with ineligible companies to disclose
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance